Transplant Complications Working Party (TCWP)
Cellular Therapy & Immunobiology Working Party (CTIWP)
Type of Stem Cell Treatment:
Chronic GVHD over time
To determine cumulative incidence of acute and chronic GvHD at 100 and 365 days, after donor-derived CAR T-cell infusion post allo-HSCT.
Key inclusion criteria:
Recipients of Allogeneic HSCT; Disease Relapse after Allogeneic HSCT; Donor derived CAR T-cell infusion after Allogeneic HSCT.